Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Byggfakta in connection with the public takeover offer from Giant BidCo
Mandate

Vinge advises Byggfakta in connection with the public takeover offer from Giant BidCo

January 05, 2024 EU, Competition and Regulatory Banking and Finance

Vinge has advised Byggfakta Group Nordic HoldCo AB (publ) in connection with a public takeover offer provided by Stirling Square, TA Associates and Macquarie Capital, through Giant BidCo, to the shareholders of Byggfakta. The offer price is SEK 46 per share and values Byggfakta to approximately SEK 10.1 billion.

Vinge’s team primarily consists of Anders Strid and Edin Agic as well as Anna Palmérus (EU & Antitrust) and Albert Wållgren (Banking & Finance).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026